ReviewNuclear medicine and molecular imaging2018
Factors Associated with Dose Determination of Radioactive Iodine Therapy for Differentiated Thyroid Cancer.
Review in Nuclear medicine and molecular imaging, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 18 citations in OpenAlex.
- DNA damage in thyroid cancer patients treated with radioactive iodine in Johannesburg, South Africa.EJNMMI reports · 2026Article
- Pre- and Post-Radioactive Iodine Therapy Hormonal Changes and Clinical Outcomes in Hyperthyroid Patients: A Retrospective Cohort Study.Pakistan journal of medical sciences · 2026Article
- Monitoring Cytogenetic Effects in Peripheral Blood Lymphocytes of Thyroid Cancer Patients Receiving Radioiodine Treatment.International journal of molecular sciences · 2026Article
- Evaluation of Dry Eye Parameters in Patients with Papillary Thyroid Carcinoma.Journal of clinical medicine · 2026Article
- Leveraging the transcriptome-phenotype relationship to guide clinical management of papillary thyroid cancer.Frontiers in endocrinology · 2026Review
- Radioactive Iodine in Differentiated Carcinoma of Thyroid: An Overview.Current radiopharmaceuticals · 2024Review
- Assessment of Different Radioiodine Doses for Post-ablation Therapy of Thyroid Remnants: A Systematic Review.Iranian journal of pharmaceutical research : IJPR · 2022Review
- Radioactive iodine therapy: multiple faces of the same polyhedron.Archives of endocrinology and metabolism · 2022Review
- Incidence rate and factors associated with the development of secondary cancers after radioiodine therapy in differentiated thyroid cancer: a multicenter retrospective study.European journal of nuclear medicine and molecular imaging · 2022Article
- A practical individualized radiation precaution based on the dose rate at release time after inpatient 131I ablation therapy.PloS one · 2021Article
- Personalized management of differentiated thyroid cancer in real life - practical guidance from a multidisciplinary panel of experts.Endocrine · 2020Review
- Reduction of Salivary Gland Damage During Radioiodine Therapy for Differentiated Thyroid Cancers.Nuclear medicine and molecular imaging · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Radioactive iodine (RAI) therapy for differentiated thyroid cancer has been successfully used for more than 70 years. However, there is still plenty of controversy surrounding the use and doses of radioiodine. There is insufficient evidence to answer the questions. Recent American Thyroid Association (ATA) guidelines seem to favor low-dose RAI, based on recent clinical trials and meta-analyses. However, long-term follow-up data remains limited, and there are additional factors we should consider that might affect the efficacy of RAI therapy. Therefore, until sufficient data are available, it is necessary to remain cautious about determining RAI doses by considering multiple patient-specific variables.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.